Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease
Open accessAbstract
Cerebral spinal fluid (CSF) Aβ42, tau and p181tau are widely accepted biomarkers of Alzheimer's disease (AD). Numerous studies show that CSF tau and p181tau levels are elevated in mild-to-moderate AD compared to age-matched controls. In addition, these increases might predict preclinical AD in cognitively normal elderly. Despite their importance as biomarkers, the molecular nature of CSF tau and ptau is not known. In the current study, reverse-phase high performance liquid chromatography was used to enrich and concentrate tau prior to western-blot analysis. Multiple N-terminal and mid-domain fragments of tau were detected in pooled CSF with apparent sizes ranging from <20 kDa to ~40 kDa. The pattern of tau fragments in AD and control samples were similar. In contrast, full-length tau and C-terminal-containing fragments were not detected. To quantify levels, five tau ELISAs and three ptau ELISAs were developed to detect different overlapping regions of the protein. The discriminatory potential of each assay was determined using 20 AD and 20 age-matched control CSF samples. Of the tau ELISAs, the two assays specific for tau containing N-terminal sequences, amino acids 9-198 (numbering based on tau 441) and 9-163, exhibited the most significant differences between AD and control samples. In contrast, CSF tau was not detected with an ELISA specific for a more C-terminal region (amino acids 159-335). Significant discrimination was also observed with ptau assays measuring amino acids 159-p181 and 159-p231. Interestingly, the discriminatory potential of p181 was reduced when measured in the context of tau species containing amino acids 9-p181. Taken together, these results demonstrate that tau in CSF occurs as a series of fragments and that discrimination of AD from control is dependent on the subset of tau species measured. These assays provide novel tools to investigate CSF tau and ptau as biomarkers for other neurodegenerative diseases.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In CSF, full-length tau can only be detected by western blot, but not by other methods such as ELISA and IP-MS.
“In CSF, full-length tau can only be detected by western blot, but not by other methods such as ELISA and IP-MS [216–219].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [217]
Both full-length and truncated tau isoforms can be secreted.
“Both full-length and truncated tau isoforms can be secreted.”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [217]
The presence of full-length tau in the CSF is questionable.
“whereas the presence of full-length tau in the CSF is questionable.”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [217]
Only the existence of truncated tau in CSF has been confirmed.
“However, only the existence of truncated tau in CSF has been confirmed [216–218]”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [217]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · see citing works
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134 · see citing works
Self-citationCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · see citing works
Self-citationHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · see citing works
Self-citationFagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246 · see citing works
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176 · see citing works
Saman, S., Kim, W., Raya, M., Visnick, Y., Miro, S., Saman, S., Jackson, B., McKee, A. C., Alvarez, V. E., Lee, N. C. Y., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.277061 · Cited by 985 · see citing works
Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896 · see citing works
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789 · see citing works
Self-citationPET imaging of amyloid deposition in patients with mild cognitive impairment
Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A. E., Ringheim, A., Långström, B., & Nordberg, A. K. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.029 · Cited by 725 · see citing works
Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy
Borroni, B., Malinverno, M., Gardoni, F., Alberici, A., Parnetti, L., Premi, E., Bonuccelli, U., Grassi, M., Perani, D., Calabresi, P., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000335941.68602.39 · Cited by 677 · see citing works
Buchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664 · see citing works
Physiological release of endogenous tau is stimulated by neuronal activity
Pooler, A. M., Phillips, E. C., Lau, D. H. W., Noble, W., & Hanger, D. P. (2013) · The EMBO Reports · doi:10.1038/embor.2013.15 · Cited by 642 · see citing works
Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70139-5 · Cited by 614 · see citing works
Self-citationCSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
Strozyk, D., Blennow, K., White, L. R., & Launer, L. J. (2003) · Neurology · doi:10.1212/01.wnl.0000046581.81650.d0 · Cited by 604 · see citing works
Self-citationVanmechelen, E., Vanderstichele, H., Davidsson, P., Kerschaver, E. V., Perre, B. V. D., Sjögren, M. J. C., Andreasen, N. C., & Blennow, K. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01036-3 · Cited by 487 · see citing works
Self-citationHampel, H., Buerger, K., Zinkowski, R., Teipel, S. J., Goernitz, A., Andreasen, N., Sjoegren, M., DeBernardis, J., Kerkman, D., Ishiguro, K., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.95 · Cited by 434 · see citing works
Self-citationThe Structural Basis of Monoclonal Antibody Alz50's Selectivity for Alzheimer's Disease Pathology
Carmel, G., Mager, E. M., Binder, L. I., & Kuret, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32789 · Cited by 402 · see citing works
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
(2012) · New England Journal of Medicine · doi:10.1056/nejmx120056 · Cited by 382 · see citing works
Goedert, M., Jakes, R., Crowther, R. A., Cohen, P., Vanmechelen, E., Vandermeeren, M., & Cras, P. (1994) · Biochemical Journal · doi:10.1042/bj3010871 · Cited by 375 · see citing works
Fagan, A. M., Mintun, M. A., Shah, A. R., Aldea, P., Roe, C. M., Mach, R. H., Marcus, D., Morris, J. C., & Holtzman, D. M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900048 · Cited by 353 · see citing works
Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease
Arai, H., Terajima, M., Miura, M., Higuchi, S., Muramatsu, T., Machida, N., Seiki, H., Takase, S., Clark, C., Lee, V. M., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380414 · Cited by 314 · see citing works
Büerger, K., Zinkowski, R. P., Teipel, S. J., Tapiola, T., Arai, H., Blennow, K., Andreasen, N., Hofmann‐Kiefer, K., DeBernardis, J. F., Kerkman, D. J., et al. (2002) · Archives of Neurology · doi:10.1001/archneur.59.8.1267 · Cited by 275 · see citing works
Self-citationItoh, N., Arai, H., Urakami, K., Ishiguro, K., Ohno, H., Hampel, H., Buerger, K., Wiltfang, J., Otto, M., Kretzschmar, H., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1054 · Cited by 256 · see citing works
Both total and phosphorylated tau are increased in Alzheimer's disease
Sjögren, M. J. C. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.5.624 · Cited by 254 · see citing works
Vigo‐Pelfrey, C., Seubert, P., Barbour, R., Blomquist, C., Lee, M., Lee, D., Coria, F., Chang, L., Miller, B. L., Lieberburg, I. M., et al. (1995) · Neurology · doi:10.1212/wnl.45.4.788 · Cited by 225 · see citing works
Constitutive secretion of tau protein by an unconventional mechanism
Chai, X., Dage, J. L., & Citron, M. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.05.021 · Cited by 224 · see citing works
Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury
Franz, G., Beer, R., Kampfl, A., Engelhardt, K., Schmutzhard, E., Ulmer, H., & Deisenhammer, F. (2003) · Neurology · doi:10.1212/01.wnl.0000063313.57292.00 · Cited by 217 · see citing works
Cerebrospinal Fluid Markers for Alzheimer's Disease Evaluated after Acute Ischemic Stroke
Hesse, C., Rosengren, L., Vanmechelen, E., Vanderstichele, H., Jensen, C., Davidsson, P., & Blennow, K. (2000) · Journal of Alzheimer s Disease · doi:10.3233/jad-2000-23-402 · Cited by 215 · see citing works
Self-citationGhoshal, N. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.8014 · Cited by 192 · see citing works
Quantification of Axonal Damage in Traumatic Brain Injury
Zemlan, F. P., Rosenberg, W. S., Luebbe, P., Campbell, T. A., Dean, G. E., Weiner, N. E., Cohen, J. A., Rudick, R. A., & Woo, D. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720741.x · Cited by 187 · see citing works
Hu, Y., He, S., Wang, X., Duan, Q., Grundke, I., Iqbal, K., & Wang, J. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62554-0 · Cited by 180 · see citing works
Alzheimer‐related neuronal protein A68: Specificity and distribution
Wolozin, B. L., & Davies, P. (1987) · Annals of Neurology · doi:10.1002/ana.410220412 · Cited by 178 · see citing works
Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury
Blennow, K., & Nellgård, B. (2004) · Neurology · doi:10.1212/wnl.62.1.159 · Cited by 176 · see citing works
Self-citationPhosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease
Ishiguro, K., Ohno, H., Arai, H., Yamaguchi, H., Urakami, K., Park, J., Sato, K., Kohno, H., & Imahori, K. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00476-0 · Cited by 175 · see citing works
Kohnken, R. E., Büerger, K., Zinkowski, R. P., Miller, C., Kerkman, D. J., DeBernardis, J. F., Shen, J., Möller, H., Davies, P., & Hampel, H. J. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01178-2 · Cited by 173 · see citing works
Age and diagnostic performance of Alzheimer disease CSF biomarkers
Mattsson, N., Rosén, E., Hansson, O., Andreasen, N. C., Parnetti, L., Jonsson, M. A. G., Herukka, S., van der Flier, W. M., Blankenstein, M. A., Ewers, M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182477eed · Cited by 166 · see citing works
Self-citationJohnson, G. V. W., Seubert, P., Cox, T. M., Motter, R., Brown, J. P., & Galasko, D. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68010430.x · Cited by 162 · see citing works
Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles
Simón, D., García‐García, E., Royo, F., Falcón‐Pérez, J. M., & Ávila, J. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.11.022 · Cited by 156 · see citing works
Hoffmann, R., Lee, V. M. ‐., Leight, S., Varga, I., & Ötvös, L. (1997) · Biochemistry · doi:10.1021/bi970380+ · Cited by 152 · see citing works
Hyperphosphorylation and Cleavage at D421 Enhance Tau Secretion
Plouffe, V., Mohamed, N., Rivest‐McGraw, J., Bertrand, J., Lauzon, M., & Leclerc, N. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036873 · Cited by 146 · see citing works
Wang, Y., Garg, S., Mandelkow, E., & Mandelkow�, E. (2010) · Biochemical Society Transactions · doi:10.1042/bst0380955 · Cited by 139 · see citing works
Mori, H., Hosoda, K., Matsubara, E., Nakamoto, T., Furiya, Y., Endoh, R., Usami, M., Shoji, M., Maruyama, S., & Hirai, S. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11291-4 · Cited by 128 · see citing works
Porzig, R., Singer, D. L., & Hoffmann, R. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.04.187 · Cited by 117 · see citing works
Cleavage of Tau by calpain in Alzheimer's disease: the quest for the toxic 17 kD fragment
Garg, S., Timm, T., Mandelkow, E.-M., Mandelkow, E., & Wang, Y. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.09.008 · Cited by 103 · see citing works
Pattern of Tau forms in CSF is altered in progressive supranuclear palsy
Borroni, B., Gardoni, F., Parnetti, L., Magno, L., Malinverno, M., Saggese, E., Calabresi, P., Spillantini, M. G., Padovani, A., & Luca, M. D. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.05.009 · Cited by 100 · see citing works
Tau Overexpression Results in Its Secretion via Membrane Vesicles
Simón, D., García‐García, E., Gómez‐Ramos, A., Falcón‐Pérez, J. M., Dı́az-Hernández, M., Hernández, F., & Ávila, J. (2012) · Neurodegenerative Diseases · doi:10.1159/000334915 · Cited by 99 · see citing works
Tau Transgenic Mice as Models for Cerebrospinal Fluid Tau Biomarkers
Barten, D. M., Cadelina, G. W., Hoque, N., DeCarr, L. B., Guss, V. L., Yang, L., Sankaranarayanan, S., Wes, P. D., Flynn, M. E., Meredith, J. E., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110161 · Cited by 87 · see citing works
Self-citationKim, W., Lee, S., & Hall, G. F. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.05.042 · Cited by 78 · see citing works
Luk, C. Y., Compta, Y., Magdalinou, N. K., Martı́, M. J., Hondhamuni, G., Zetterberg, H., Blennow, K., Constantinescu, R., Pijnenburg, Y. A. L., Mollenhauer, B., et al. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07911.x · Cited by 62 · see citing works
Self-citationTau cleavage and tau aggregation in neurodegenerative disease
Hanger, D. P., & Wray, S. (2010) · Biochemical Society Transactions · doi:10.1042/bst0381016 · Cited by 60 · see citing works
Bahl, J. M. C., Heegaard, N. H. H., Falkenhorst, G., Laursen, H. B., Høgenhaven, H., Mølbak, K., Jespersgaard, C., Hougs, L., Waldemar, G., Johannsen, P., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.01.013 · Cited by 55 · see citing works
Mercken, M. H., Vandermeeren, M., Lübke, U., Six, J., Boons, J., Vanmechelen, E., VOORDE, A. V. D., & Gheuens, J. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09754.x · Cited by 49 · see citing works
Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview
Morris, J. C., & Selkoe, D. J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.005 · Cited by 37 · see citing works
Measurement of Aβ1–42 in cerebrospinal fluid is influenced by matrix effects
Slemmon, J. R., Meredith, J. E., Guss, V. L., Andréasson, U., Andreasen, N., Zetterberg, H., & Blennow, K. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07553.x · Cited by 34 · see citing works
Self-citationCerebrospinal Fluid Biomarkers for Alzheimer's Disease: More to Come?
Zetterberg, H., & Blennow, K. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129035 · Cited by 33 · see citing works
Self-citationDiagnosis of progressive supranuclear palsy: can measurement of tau forms help?
Kuiperij, H. B., & Verbeek, M. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.08.011 · Cited by 24 · see citing works
Singer, D. L., Soininen, H. S., Alafuzoff, I. I., & Hoffmann, R. (2009) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-009-3208-8 · Cited by 21 · see citing works
Analysis of Human Tau in Cerebrospinal Fluid
Hanisch, K., Soininen, H., Alafuzoff, I., & Hoffmann, R. (2010) · Journal of Proteome Research · doi:10.1021/pr901002t · Cited by 17 · see citing works
Enrichment and analysis of Alzheimer's Aβ1-42 peptide in human plasma and whole blood
Ditto, N. T., Kline, T. R., Alfinito, P. D., & Slemmon, J. R. (2009) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2009.05.025 · Cited by 11 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Biomarkers for Alzheimer's disease: current status and prospects for the future
Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000 · see citing works
Self-citationMolecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994 · see citing works
Tau PET imaging in neurodegenerative tauopathies—still a challenge
Leuzy, A., Chiotis, K., Lemoine, L., Gillberg, P.-G., Almkvist, O., Rodriguez-Vieitez, E., & Nordberg, A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0342-8 · Cited by 628 · see citing works
Tau Kinetics in Neurons and the Human Central Nervous System
Sato, C., Barthélemy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.015 · Cited by 586 · see citing works
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518 · see citing works
Self-citationSuárez‐Calvet, M., Karikari, T. K., Ashton, N. J., Lantero Rodríguez, J., Milà‐Alomà, M., Gispert, J. D., Salvadó, G., Minguillon, C., Fauria, K., Shekari, M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012921 · Cited by 401 · see citing works
Self-citationWang, C., Ward, M. E., Chen, R., Liu, K., Tracy, T. E., Chen, X., Xie, M., Sohn, P. D., Ludwig, C., Meyer-Franke, A., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.08.019 · Cited by 400 · see citing works
Kvartsberg, H., Duits, F. H., Ingelsson, M., Andreasen, N., Öhrfelt, A., Andersson, K., Brinkmalm, G., Lannfelt, L., Minthon, L., Hansson, O., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.10.009 · Cited by 339 · see citing works
Self-citationBlood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Karikari, T. K., Ashton, N. J., Brinkmalm, G., Brum, W. S., Benedet, A. L., Montoliu‐Gaya, L., Lantero‐Rodriguez, J., Pascoal, T. A., Suárez‐Calvet, M., Rosa‐Neto, P., et al. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00665-2 · Cited by 327 · see citing works
Self-citationRole of Amyloid-β and Tau Proteins in Alzheimer’s Disease: Confuting the Amyloid Cascade
Gulisano, W., Maugeri, D., Baltrons, M. A., Fà, M., Amato, A., Palmeri, A., D’Adamio, L., Grassi, C., Devanand, D. P., Honig, L. S., et al. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179935 · Cited by 313 · see citing works
Tau immunotherapy for Alzheimer's disease
Pedersen, J. T., & Sigurdsson, E. M. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.03.003 · Cited by 247 · see citing works
Human secreted tau increases amyloid-beta production
Bright, J., Hussain, S., Dang, V., Wright, S., Cooper, B., Byun, T., Ramos, C., Singh, A., Parry, G., Stagliano, N., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.09.007 · Cited by 230 · see citing works
Schöll, M., Maaß, A., Mattsson, N., Ashton, N. J., Blennow, K., Zetterberg, H., & Jagust, W. J. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.12.001 · Cited by 227 · see citing works
Self-citationCerebrospinal fluid tau and amyloid-β1-42in patients with dementia
Skillbäck, T. B., Farahmand, B. Y., Rosén, C., Mattsson, N., Nägga, K., Kilander, L., Religa, D., Wimo, A. B., Winblad, B. G., Schott, J. M., et al. (2015) · Brain · doi:10.1093/brain/awv181 · Cited by 215 · see citing works
Self-citationMolinuevo, J. L., Blennow, K., Dubois, B., Engelborghs, S., Lewczuk, P., Perret‐Liaudet, A., Teunissen, C. E., & Parnetti, L. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.03.003 · Cited by 198 · see citing works
Self-citationTau passive immunization inhibits not only tau but also Aβ pathology
Dai, C., Tung, Y. C., Liu, F., Gong, C., & Iqbal, K. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0227-5 · Cited by 186 · see citing works
Detection of Aggregation-Competent Tau in Neuron-Derived Extracellular Vesicles
Guix, F. X., Corbett, G. T., Cha, D., Mustapić, M., Liu, W., Mengel, D., Chen, Z., Aïkawa, E., Young‐Pearse, T. L., Kapogiannis, D., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030663 · Cited by 182 · see citing works
Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers
Quinn, J. P., Corbett, N. J., Kellett, K. A. B., & Hooper, N. M. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-170959 · Cited by 170 · see citing works
CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease
Horie, K., Barthélemy, N. R., Sato, C., & Bateman, R. J. (2021) · Brain · doi:10.1093/brain/awaa373 · Cited by 180 · see citing works
MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways
Fatimy, R. E., Li, S., Chen, Z., Mushannen, T., Gongala, S., Wei, Z., Balu, D. T., Rabinovsky, R., Cantlon, A., Elkhal, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1880-5 · Cited by 172 · see citing works
Cicognola, C., Brinkmalm, G., Wahlgren, J., Portelius, E., Gobom, J., Cullen, N. C., Hansson, O., Parnetti, L., Constantinescu, R., Wildsmith, K., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1948-2 · Cited by 168 · see citing works
Self-citationKanmert, D., Cantlon, A., Muratore, C., Jin, M., O’Malley, T. T., Lee, G. S., Young‐Pearse, T. L., Selkoe, D. J., & Walsh, D. M. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0387-15.2015 · Cited by 159 · see citing works
Review: Tau in biofluids – relation to pathology, imaging and clinical features
Zetterberg, H. (2017) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12378 · Cited by 157 · see citing works
Self-citationAmyloid β-protein and beyond: the path forward in Alzheimer’s disease
Walsh, D. M., & Selkoe, D. J. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2020.02.003 · Cited by 160 · see citing works
Dage, J. L., Wennberg, A. M. V., Airey, D. C., Hagen, C. E., Knopman, D. S., Machulda, M. M., Roberts, R. O., Jack, C. R., Petersen, R. C., & Mielke, M. M. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.001 · Cited by 145 · see citing works
Vos, A. D., Jacobs, D., Struyfs, H., Fransén, E., Andersson, K., Portelius, E., Andréasson, U., Surgeloose, D. D., Hernalsteen, D., Sleegers, K., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.012 · Cited by 158 · see citing works
Self-citationBarthélemy, N. R., Saef, B., Li, Y., Gordon, B. A., He, Y., Horie, K., Stomrud, E., Salvadó, G., Janelidze, S., Sato, C., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00380-7 · Cited by 153 · see citing works
The Past and the Future of Alzheimer’s Disease Fluid Biomarkers
Blennow, K., & Zetterberg, H. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170773 · Cited by 148 · see citing works
Self-citationDam, T., Boxer, A. L., Golbe, L. I., Höglinger, G. U., Morris, H. R., Litvan, I., Lang, A. E., Corvol, J., Aiba, I., Grundman, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01455-x · Cited by 146 · see citing works
Sankaranarayanan, S., Barten, D. M., Vana, L., Devidze, N., Yang, L., Cadelina, G. W., Hoque, N., DeCarr, L. B., Keenan, S., Lin, A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125614 · Cited by 143 · see citing works
Self-citationYang, C., Chiu, M., Chen, T., Chang, H.-L., Liu, B.-H., & Yang, S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170810 · Cited by 143 · see citing works
Karikari, T. K., Emeršič, A., Vrillon, A., Lantero‐Rodriguez, J., Ashton, N. J., Kramberger, M. G., Dumurgier, J., Hourregue, C., Čučnik, S., Brinkmalm, G., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12236 · Cited by 143 · see citing works
Self-citationBarthélemy, N. R., Gabelle, A., Hirtz, C., Fenaille, F., Sergeant, N., Schraen-Maschke, S., Vialaret, J., Buée, L., Junot, C., Becher, F., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150962 · Cited by 139 · see citing works
Boxer, A., Qureshi, I., Ahlijanian, M., Grundman, M., Golbe, L., Litvan, I., Honig, L. S., Tuite, P., McFarland, N. R., O'Suilleabhain, P., et al. (2019) · Lancet Neurology · doi:10.1016/s1474-4422(19)30139-5 · Cited by 115 · see citing works
Self-citationRoberts, M., Sevastou, I., Imaizumi, Y., Mistry, K., Talma, S., Dey, M., Gartlon, J., Ochiai, H., Zhou, Z., Akasofu, S., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-0884-2 · Cited by 135 · see citing works
New Insights Into Drug Discovery Targeting Tau Protein
Soeda, Y., & Takashima, A. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.590896 · Cited by 133 · see citing works
Wagshal, D., Sankaranarayanan, S., Guss, V., Hall, T., Berisha, F., Lobach, I., Karydas, A., Voltarelli, L., Scherling, C., Heuer, H., et al. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308004 · Cited by 132 · see citing works
Self-citationCourade, J., Angers, R. C., Mairet‐Coello, G., Pacico, N., Tyson, K. L., Lightwood, D. J., Munro, R., McMillan, D., Griffin, R., BAKER, T. S., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1911-2 · Cited by 131 · see citing works
Leuzy, A., Janelidze, S., Mattsson-Carlgren, N., Palmqvist, S., Jacobs, D., Cicognola, C., Stomrud, E., Vanmechelen, E., Dage, J. L., & Hansson, O. (2021) · Neurology · doi:10.1212/wnl.0000000000012727 · Cited by 128 · see citing works
Nobuhara, C. K., DeVos, S. L., Commins, C., Wegmann, S., Moore, B. D., Roe, A. D., Costantino, I., Frosch, M. P., Pitstick, R., Carlson, G. A., et al. (2017) · The American Journal of Pathology · doi:10.1016/j.ajpath.2017.01.022 · Cited by 120 · see citing works
Xu, Y., Du, S., Marsh, J. A., Horie, K., Sato, C., Ballabio, A., Karch, C. M. M., Holtzman, D. M., & Zheng, H. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0738-0 · Cited by 121 · see citing works
Barthélemy, N. R., Fenaille, F., Hirtz, C., Sergeant, N., Schraen-Maschke, S., Vialaret, J., Buée, L., Gabelle, A., Junot, C., Lehmann, S., et al. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b01001 · Cited by 123 · see citing works
Chen, Z., Mengel, D., Keshavan, A., Rissman, R. A., Billinton, A., Perkinton, M. S., Percival‐Alwyn, J., Schultz, A. P., Properzi, M. J., Johnson, K. A., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.09.010 · Cited by 114 · see citing works
Self-citationCerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology
Blennow, K., Chen, C., Cicognola, C., Wildsmith, K. R., Manser, P. T., Bohorquez, S. M. S., Zhang, Z., Xie, B., Peng, J., Hansson, O., et al. (2020) · Brain · doi:10.1093/brain/awz346 · Cited by 105 · see citing works
Self-citationChen, X., Li, Y., Wang, C., Tang, Y., Mok, S., Tsai, R. M., Rojas, J. C., Karydas, A., Miller, B. L., Boxer, A. L., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0354-0 · Cited by 113 · see citing works
Alawode, D. O. T., Heslegrave, A., Ashton, N. J., Karikari, T. K., Simrén, J., Montoliu‐Gaya, L., Pannee, J., O’Connor, A., Weston, P. S. J., Lantero‐Rodriguez, J., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13332 · Cited by 100 · see citing works
Self-citationDai, C.-L., Hu, W., Tung, Y. C., Liu, F., Gong, C.-X., & Iqbal, K. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0341-7 · Cited by 99 · see citing works
Cascaded multi-modal mixing transformers for Alzheimer’s disease classification with incomplete data
Liu, L., Liu, S., Zhang, L., To, X. V., Nasrallah, F., & Chandra, S. S. (2023) · NeuroImage · doi:10.1016/j.neuroimage.2023.120267 · Cited by 101 · see citing works
Current Status of Clinical Trials on Tau Immunotherapies
Ji, C., & Sigurdsson, E. M. (2021) · Drugs · doi:10.1007/s40265-021-01546-6 · Cited by 96 · see citing works
Targeting tau: clinical trials and novel therapeutic approaches
VandeVrede, L., Boxer, A. L., & Polydoro, M. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.134919 · Cited by 90 · see citing works
Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies
Vogels, T., Leuzy, A., Cicognola, C., Ashton, N. J., Smolek, T., Novák, M., Blennow, K., Zetterberg, H., Hromádka, T., Žilka, N., et al. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.09.019 · Cited by 94 · see citing works
Self-citationCerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions
Magdalinou, N. K., Lees, A. J., & Zetterberg, H. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-307539 · Cited by 93 · see citing works
Self-citationA randomized, single ascending dose study of intravenous BIIB092 in healthy participants
Qureshi, I., Tirucherai, G., Ahlijanian, M. K., Kolaitis, G., Bechtold, C. M., & Grundman, M. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.10.007 · Cited by 90 · see citing works
Self-citationTau immunotherapies: Lessons learned, current status and future considerations
Sandusky-Beltran, L. A., & Sigurdsson, E. M. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108104 · Cited by 90 · see citing works
Blennow, K., & Zetterberg, H. (2015) · Nature Medicine · doi:10.1038/nm.3810 · Cited by 80 · see citing works
Self-citationKim, H., Lee, J. U., Kim, S., Song, S., & Sim, S. J. (2019) · ACS Sensors · doi:10.1021/acssensors.8b01242 · Cited by 73 · see citing works
Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force
Cummings, J. L., Blennow, K., Johnson, K. A., Keeley, M. B., Bateman, R. J., Molinuevo, J. L., Touchon, J., Aisen, P. S. S., & Vellas, B. J. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.14 · Cited by 71 · see citing works
Self-citationLeuzy, A., Ashton, N. J., Mattsson, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A. E., Nordberg, A. K., Ossenkoppele, R., Zetterberg, H., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05258-7 · Cited by 69 · see citing works
Self-citationTau pathology in Creutzfeldt‐Jakob disease revisited
Kovács, G. G., Rahimi, J., Ströbel, T., Lutz, M. I., Regelsberger, G., Streichenberger, N., Perret‐Liaudet, A., Höftberger, R., Liberski, P. P., Budka, H., et al. (2016) · Brain Pathology · doi:10.1111/bpa.12411 · Cited by 68 · see citing works
Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
Triana‐Baltzer, G., Moughadam, S., Slemmon, R., Kolen, K. V., Theunis, C., Mercken, M. H., & Kolb, H. C. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12204 · Cited by 61 · see citing works
Ultra-sensitive detection of protein biomarkers for diagnosis of Alzheimer’s disease
Chan, H., Xu, D., Ho, S., Wong, M. S., & Li, H. (2017) · Chemical Science · doi:10.1039/c6sc05615f · Cited by 65 · see citing works
Fichou, Y., Al‐Hilaly, Y. K., Devred, F., Smet‐Nocca, C., Tsvetkov, P. O., Verelst, J., Winderickx, J., Geukens, N., Vanmechelen, E., Perrotin, A., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0682-x · Cited by 63 · see citing works
Characterization of tau binding by gosuranemab
Sopko, R., Golonzhka, O., Arndt, J. W., Quan, C., Czerkowicz, J., Cameron, A., Smith, B., Yogapriya, M., Gibbons, G. S., Kim, S., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105120 · Cited by 64 · see citing works
Brureau, A., Blanchard-Bregeon, V., Pech, C., Hamon, S., Chaillou, P., Guillemot, J.-C., Barneoud, P., Bertrand, P., Pradier, L., Rooney, T., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.04.007 · Cited by 62 · see citing works
Muraoka, S., Jedrychowski, M. P., Tatebe, H., DeLeo, A. M., Ikezu, S., Tokuda, T., Gygi, S. P., Stern, R. A., & Ikezu, T. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01059 · Cited by 62 · see citing works
Russell, C. L., Mitra, V., Hansson, K., Blennow, K., Gobom, J., Zetterberg, H., Hiltunen, M., Ward, M., & Pike, I. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160633 · Cited by 52 · see citing works
Self-citationTau Secretion: Good and Bad for Neurons
Pernègre, C., Duquette, A., & Leclerc, N. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00649 · Cited by 62 · see citing works
Gobom, J., Benedet, A. L., Mattsson, N., Montoliu‐Gaya, L., Schultz, N., Ashton, N. J., Janelidze, S., Servaes, S., Sauer, M., Pascoal, T. A., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00586-0 · Cited by 57 · see citing works
Self-citationIntrinsic Tau Acetylation Is Coupled to Auto-Proteolytic Tau Fragmentation
Cohen, T. J., Constance, B. H., Hwang, A. W., James, M., & Yuan, C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158470 · Cited by 56 · see citing works
Calpain-mediated tau fragmentation is altered in Alzheimer’s disease progression
Chen, H.-H., Liu, P., Auger, P., Lee, S.-H., Adolfsson, O., Rey-Bellet, L., Lafrance-Vanasse, J., Friedman, B. A., Pihlgren, M., Muhs, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-35130-y · Cited by 51 · see citing works
Methods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative Dementias
Teunissen, C. E., Kimble, L. E., Bayoumy, S., Bolsewig, K., Burtscher, F., Coppens, S., Das, S., Gogishvili, D., Gomes, B. F., José, N. G. D. S., et al. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100629 · Cited by 58 · see citing works
Self-citationQuantification of Tau Protein Lysine Methylation in Aging and Alzheimer’s Disease
Huseby, C. J., Hoffman, C. N., Cooper, G. L., Cocuron, J.-C., Alonso, A. P., Thomas, S. N., Yang, A. J., & Kuret, J. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190604 · Cited by 54 · see citing works
N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases
Snellman, A., Lantero‐Rodriguez, J., Emeršič, A., Vrillon, A., Karikari, T. K., Ashton, N. J., Kramberger, M. G., Čučnik, S., Paquet, C., Rot, U., et al. (2021) · Brain · doi:10.1093/brain/awab481 · Cited by 53 · see citing works
Self-citationWeisová, P., Cehlár, O., Škrabana, R., Žilková, M., Filipčík, P., Kováčech, B., Prčina, M., Wojčiaková, Ľ., Fialová, Ľ., Smolek, T., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0770-y · Cited by 52 · see citing works
Florenzano, F., Corsetti, V., Ciasca, G., Ciotti, M. T., Pittaluga, A., Olivero, G., Feligioni, M., Iannuzzi, F., Latina, V., Sciacca, M. F. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17371 · Cited by 52 · see citing works
Blennow, K., & Zetterberg, H. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.006 · Cited by 46 · see citing works
Self-citationImmunological memory to hyperphosphorylated tau in asymptomatic individuals
Pascual, G., Wadia, J. S., Zhu, X., Keogh, E. A., Kaletaş, B. K., van Ameijde, J., Inganäs, H., Siregar, B., Perdok, G. J., Diefenbach, O., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1705-y · Cited by 44 · see citing works
Leuzy, A., Cicognola, C., Chiotis, K., Saint‐Aubert, L., Lemoine, L., Andreasen, N., Zetterberg, H., Ye, K., Blennow, K., Höglund, K., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4242-6 · Cited by 45 · see citing works
Self-citationSimoes, S., Neufeld, J. L., Triana‐Baltzer, G., Moughadam, S., Chen, E. I., Kothiya, M., Qureshi, Y. H., Patel, V. M., Honig, L. S., Kolb, H. C., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba6334 · Cited by 44 · see citing works
Lantero‐Rodriguez, J., Salvadó, G., Snellman, A., Montoliu‐Gaya, L., Brum, W. S., Benedet, A. L., Mattsson, N., Tideman, P., Janelidze, S., Palmqvist, S., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00707-x · Cited by 42 · see citing works
Self-citationAmadoro, G., Latina, V., Corsetti, V., & Calissano, P. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165584 · Cited by 42 · see citing works
Corsetti, V., Borreca, A., Latina, V., Giacovazzo, G., Pignataro, A., Krashia, P., Natale, F., Cocco, S., Rinaudo, M., Malerba, F., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa039 · Cited by 41 · see citing works
Amadoro, G., Corsetti, V., Sancesario, G. M., Lubrano, A., Melchiorri, G., Bernardini, S., Calissano, P., & Sancesario, G. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140267 · Cited by 41 · see citing works
Yamaguchi, K., Kamatari, Y. O., Ono, F., Shibata, H., Fuse, T., Elhelaly, A. E., Fukuoka, M., Kimura, T., Hosokawa‐Muto, J., Ishikawa, T., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0349-8 · Cited by 41 · see citing works
Galectin-3 aggravates microglial activation and tau transmission in tauopathy
Siew, J. J., Chen, H.-M., Chiu, F., Lee, C., Chang, Y., Chen, H.-L., Nguyen, T. N. A., Liao, H.-T., Liu, M., Hagar, H. C., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165523 · Cited by 40 · see citing works
Knockin’ on heaven’s door: Molecular mechanisms of neuronal tau uptake
La‐Rocque, S. D., Moretto, E., Butnaru, I., & Schiavo, G. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15144 · Cited by 42 · see citing works
Tau Conformation as a Target for Disease-Modifying Therapy: The Role of Truncation
Novák, P., Cehlár, O., Škrabana, R., & Novák, M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179942 · Cited by 36 · see citing works
Blood-Derived Plasma Protein Biomarkers for Alzheimer’s Disease in Han Chinese
Cheng, Z., Yin, J., Yuan, H., Jin, C., Zhang, F., Wang, Z., Liu, X., Wu, Y., Wang, T., & Xiao, S. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00414 · Cited by 37 · see citing works
Pottiez, G., Yang, L., Stewart, T., Song, N., Aro, P., Galasko, D. R., Quinn, J. F., Peskind, E. R., Shi, M., & Zhang, J. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00829 · Cited by 37 · see citing works
Tau truncation in the pathogenesis of Alzheimer’s disease: a narrative review
Chu, D., Yang, X., Wang, J., Zhou, Y., Gu, J., Miao, J., Wu, F., & Liu, F. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.385853 · Cited by 37 · see citing works
Foiani, M. S., Cicognola, C., Ermann, N., Woollacott, I., Heller, C., Heslegrave, A., Keshavan, A., Paterson, R. W., Ye, K., Kornhuber, J., et al. (2019) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-319266 · Cited by 35 · see citing works
Self-citationAlzheimer's disease — Recent biomarker developments in relation to updated diagnostic criteria
Höglund, K., Fourier, A., Perret‐Liaudet, A., Zetterberg, H., Blennow, K., & Portelius, E. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.01.041 · Cited by 35 · see citing works
Self-citationBarthélemy, N. R., Toth, B., Manser, P. T., Sanabria-Bohórquez, S., Teng, E., Keeley, M., Bateman, R. J., Weimer, R. M., & Wildsmith, K. R. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210677 · Cited by 33 · see citing works
Lewczuk, P., Lelental, N., Lachmann, I., Holzer, M., Flach, K., Brandner, S., Engelborghs, S., Teunissen, C. E., Zetterberg, H., Molinuevo, J. L., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160448 · Cited by 33 · see citing works
Self-citationSharma, H. S., Muresanu, D. F., Nozari, A., Lafuente, J. V., Tian, Z. R., Ozkızılcık, A., Manzhulo, I., Mössler, H., & Sharma, A. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.03.009 · Cited by 33 · see citing works
Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease
Mengel, D., Janelidze, S., Glynn, R. J., Liu, W., Hansson, O., & Walsh, D. M. (2020) · Annals of Neurology · doi:10.1002/ana.25885 · Cited by 32 · see citing works
Expanding the cerebrospinal fluid endopeptidome
Hansson, K. T., Skillbäck, T. B., Pernevik, E., Kern, S., Portelius, E., Höglund, K., Brinkmalm, G., Holmén‐Larsson, J., Blennow, K., Zetterberg, H., et al. (2017) · PROTEOMICS · doi:10.1002/pmic.201600384 · Cited by 32 · see citing works
Self-citationCalderón‐Garcidueñas, L., Mukherjee, P. S., Waniek, K., Holzer, M., Chao, C., Thompson, C., Ramos, R. R., Calderón‐Garcidueñas, A. L., Franco-Lira, M., Reynoso-Robles, R., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180853 · Cited by 32 · see citing works
Tau immunization: a cautionary tale?
Mably, A. J., Kanmert, D., Donald, J. M. M., Liu, W., Caldarone, B. J., Lemere, C. A., O’Nuallain, B., Kosik, K. S., & Walsh, D. M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.11.022 · Cited by 31 · see citing works
- Authors
- Meredith Jr., J. E., Sankaranarayanan, S., Guss, V., Lanzetti, A. J., Berisha, F., Neely, R. J., Slemmon, J. R., Portelius, E., Zetterberg, H., Blennow, K., Soares, H., Ahlijanian, M., & Albright, C. F.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- University of Gothenburg (SE)
- UCL Queen Square Institute of Neurology (GB)
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-10-07
- Volume
- 8
- Issue
- 10
- Pages
- e76523
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3792042
- OpenAlex
- W2024790026
- Cited by
- 209
- References
- 60
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 14 · 2023: 14 · 2022: 11 · 2021: 19 · 2020: 23 · 2019: 28 · 2018: 29 · 2017: 16 · 2016: 11 · 2015: 13 · 2014: 11
- FWCI
- 8.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Bristol-Myers Squibb
- Vetenskapsrådet
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, cerebrospinal fluid, tau protein, phosphorylated tau, biomarkers, preclinical Alzheimer's disease, tau isoforms, diagnostic discrimination
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Chromatography, High Pressure Liquid, Enzyme-Linked Immunosorbent Assay, Humans, Male, Middle Aged, Molecular Weight, Peptide Fragments, Phosphorylation, Sensitivity and Specificity, Blotting, Western, Reproducibility of Results, Biomarkers, tau Proteins, Chromatography, Reverse-Phase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
